PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sterilox Effective against Human/Animal Influenza

30 Apr 2009 07:00

RNS Number : 4247R
PuriCore Plc
30 April 2009
 



PuriCore Confirms Effectiveness of Safe, Natural 

Sterilox Solution Against H1N1 Swine Influenza A 

Studies Show Sterilox Solution Effective against Human and Animal Influenza

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 30 April 2009 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively and naturally kill infectious pathogens without causing harm to human health or the environment, reaffirms that its Sterilox Solution has been proven highly effective against human and animal influenza. Multiple research studies showed that Sterilox Solution as a spray and in fogging form completely inactivate human influenza and H5N1 avian influenza and passed the US Environmental Protection Agency's (EPA's) recommended hard-surface disinfection test. Results of these studies were presented at the National Environmental Health Association Conference last year. Additional independent research shows that hypochlorous acid is effective in inactivating H5N1 avian influenza in water.

The Sterilox Solution mimics the natural anti-microbial hypochlorous acid produced by the human body's immune system to fight pathogens. A wide range of markets that depend upon controlling the spread of infectious pathogens-including food retail and foodservice, hospitality, medical device disinfection, and wound therapy-use PuriCore's Sterilox Systems to produce this safe, natural, and green disinfectant and sanitizer.

PuriCore advises its customers to follow the recommendations issued recently by the UK Health Protection Agency, which cites the US Centers for Disease Control and Prevention (CDC) guidelines to those in healthcare settings that "disinfection strategies used during influenza seasons can be applied to the environmental management of swine influenza." 

Mark Sampson, PhD, Director of Microbiology for PuriCore, said: 

"Given the heightened concern with H1N1 swine influenza outbreak by healthcare providers, governments, and the general population, we reaffirm that independent studies demonstrate that our safe and environmentally friendly Sterilox Solution is highly effective against animal and human influenza. Sterilox Solution can be used safely in a broad range of disinfection and sanitizing applications in a variety of settings including hotels, hospitals, schools, supermarkets, and restaurants." 

Enquiries:

Ben Brewerton

Susan Quigley

Financial Dynamics

+44 (0) 20 7831 3113

Daniel Bee, President, International and UK Managing Director 

PuriCore 

+44 1785 782420

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitization. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C. difficileE.coli, HIV, Human and Animal Influenza (including H5N1 Avian Influenza), Legionella, MRSAM.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in MalvernPennsylvania, with offices in StaffordUK

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUKOKRKURSUAR
Date   Source Headline
1st Feb 20199:12 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
31st Jan 201910:06 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
29th Jan 201910:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
25th Jan 20198:55 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
22nd Jan 20199:10 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
14th Jan 20199:44 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
11th Jan 20199:39 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
8th Jan 201910:41 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Jan 20199:46 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
3rd Jan 20199:53 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
2nd Jan 20199:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
27th Dec 201810:47 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
24th Dec 201810:18 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Dec 201810:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Dec 201810:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Dec 20188:54 amRNSForm 8.3 - Realm Therapeutics plc
19th Dec 201810:27 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
13th Dec 20189:35 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
10th Dec 20181:20 pmRNSForm 8.3 - Realm Therapeutics plc
10th Dec 201810:32 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
6th Dec 201810:46 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
5th Dec 20189:56 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Dec 201812:20 pmRNSForm 8.5 (EPT/RI) Realm therapeutics
3rd Dec 201811:20 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
30th Nov 20184:08 pmRNSHolding(s) in Company
30th Nov 20181:18 pmRNSForm 8.3 - Realm Therapeutics plc
30th Nov 201811:39 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
29th Nov 201811:58 amRNSHolding(s) in Company
29th Nov 201811:13 amRNSForm 8.3 - Realm Therapeutics plc
29th Nov 20189:55 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
29th Nov 20187:00 amRNSUpdate on Strategic Review
28th Nov 201810:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
28th Nov 20189:53 amRNSForm 8.3 - Realm Therapeutics plc
27th Nov 20186:28 pmRNSForm 8.3 - Realm Therapeutics plc
26th Nov 201811:22 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
26th Nov 20188:41 amRNSForm 8.3 - Realm Therapeutics plc
12th Nov 20188:32 amRNSForm 8.5 (EPT/RI) Realm therapeutics
7th Nov 20185:14 pmRNSHolding(s) in Company
7th Nov 201810:37 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
7th Nov 20189:03 amRNSForm 8.3 - Realm Therapeutics plc
6th Nov 201810:36 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
2nd Nov 201811:31 amRNSForm 8.3 - Realm Therapeutics plc
31st Oct 20189:04 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
25th Oct 20189:34 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Oct 201810:23 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
17th Oct 201810:37 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
16th Oct 20189:31 amRNSForm 8.5 (EPT/RI) Realm therapeutics
15th Oct 20189:34 amRNSForm 8.3 - Realm Therapeutics plc
15th Oct 20189:24 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
12th Oct 20188:58 amRNSForm 8.5 (EPT/RI) Realm Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.